- Accesswire•13 days ago
NEW YORK, NY / ACCESSWIRE / April 17, 2017 / The Biotech Industry has continued to provide solid gains for investors in 2017, despite all the negative attention the industry has received due to drug pricing ...
- Business Wire•27 days ago
Verastem, Inc. , focused on discovering and developing drugs to treat cancer, today announced that the company will present at the 16th Annual Needham Healthcare Conference on Tuesday, April 4th at 3:00 p.m.
- Business Wire•28 days ago
Data on Verastem’s Focal Adhesion Kinase Inhibitor Defactinib Presented at the 2017 American Association for Cancer Research Annual Meeting
Verastem, Inc. , focused on discovering and developing drugs to treat cancer, today announced the oral presentation of data for its lead focal adhesion kinase inhibitor, defactinib, by the Company’s scientific collaborator David G.
VSTM : Summary for Verastem, Inc. - Yahoo Finance
Verastem, Inc. (VSTM)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
|Bid||1.61 x 2000|
|Ask||2.20 x 200|
|Day's Range||1.82 - 1.94|
|52 Week Range||1.05 - 2.25|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-1.97|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|